A Phase I, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Investigate Safety and Pharmacokinetics of SHR-1314 in Healthy Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Vunakizumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Atridia
- 13 Nov 2017 Status changed from recruiting to completed.
- 27 Oct 2016 New trial record